# Cytokinetics Announces Nine Upcoming Presentations at the European Society of Cardiology Heart Failure 2026 Congress
Canonical URL: https://biopharmsignal.com/news/CYTK/cytokinetics-announces-nine-upcoming-presentations-at-the-european-society-of-ca-435365bb
Ticker: CYTK
Company: Cytokinetics
Source: Cytokinetics
Published: 2026-04-28 11:30 EST
## Summary

Cytokinetics, Incorporated (Nasdaq: CYTK) today announced nine presentations at the...

## Article Body
Cytokinetics, Incorporated (Nasdaq: CYTK) today announced nine presentations at the European Society of Cardiology Heart Failure 2026 Congress taking place in Barcelona, Spain, from May 9–12, 2026. Eight presentations, including a late-breaking science oral presentation, are related to MYQORZO ® (aficamten). Recently approved for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) by the U.S. Food and Drug Administration, European Commission, and the China National Medical Products Administration, MYQORZO is an allosteric and reversible inhibitor of cardiac myosin motor activity. In patients with oHCM, myosin inhibition with MYQORZO reduces cardiac contractility and consequently, left ventricular outflow tract (LVOT) obstruction.

Late Breaking Science Oral Presentation

Title : Dose-dependent effects of aficamten compared with metoprolol in obstructive HCM: the MAPLE-HCM study Presenter : Pablo Garcia-Pavia, M.D., Ph.D., Head of the Inherited Cardiac Diseases and Heart Failure Unit, Department of Cardiology, Hospital Universitario Puerta de Hierro and Full Professor at Centro Nacional de Investigaciones Cardiovasculares, Madrid, Spain Date: May 11, 2026 Session Title: Advances in Cardiomyopathies Session Time : 3:30 PM – 4:30 PM CEST Presentation Time: 4:06 PM – 4:18 PM CEST Location: Room 3

Rapid Fire Presentations

Title : Favorable Effect of Aficamten on Left Atrial Mechanics in Obstructive Hypertrophic Cardiomyopathy: Insights From the SEQUOIA-HCM Trial Presenter : Yasuhiro Hamatani, M.D., Ph.D., Postdoctoral Fellow, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA Date: May 9, 2026 Session Title: Advanced Phenotyping and Risk Stratification in Cardiomyopathies and Myocarditis Session Time : 3:30 PM – 4:30 PM CEST Presentation Time: 3:47 PM – 3:55 PM CEST Location: Agora 2

Title : Effect of Aficamten Compared with Metoprolol in Women Versus Men: Analysis of MAPLE-HCM Presenter: Xiaowen Wang, MD, MPH, Associate Director, Cardiac Imaging Core Lab, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA Date: May 10, 2026 Session Title: Novel and Targeted Therapies: Precision Pharmacology in Heart Failure Session Time : 2:30 PM – 3:15 PM CEST Presentation Time: 2:57 PM – 3:06 PM CEST Location: Agora 2

In addition to the rapid fire presentations related to MYQORZO ® (aficamten ), one presentation will offer further insights into the treatment effect of omecamtiv mecarbil in heart failure with reduced ejection fraction (HFrEF).

Title: The Influence of QRS Duration and Resynchronization Status on the Efficacy and Safety of Omecamtiv Mecarbil in Heart Failure with Reduced Ejection Fraction: The GALACTIC-HF Trial Presenter: Mihály Ruppert, MD, PhD, Researh Fellow, Brigham and Women's Hospital, Boston, MA, USA Date: May 10, 2026 Session Title: Novel and Targeted Therapies: Precision Pharmacology in Heart Failure Session Time : 2:30 PM – 3:15 PM CEST Presentation Time: 2:39 PM – 2:48 PM CEST Location: Agora 2

Moderated Posters

Title: No Increase in Arrhythmia Burden Following Aficamten Treatment in Obstructive Hypertrophic Cardiomyopathy: Extended Ambulatory Electrocardiogram Analysis From FOREST-HCM Presenter: Ethan J. Rowin, M.D., Associate Professor of Medicine at UMass Chan-Lahey, UMass Chan Medical School, Lahey Hospital & Medical Center, Burlington, MA Date: May 11, 2026 Session Title: Hypertrophic Obstructive Cardiomyopathy: Treatment, Monitoring, and Outcomes Session Time : 1:30 PM – 2:15 PM CEST Location: Moderated ePosters 3

Title: Clinical and Economic Burden in NYHA Class I Versus II-IV Hypertrophic Cardiomyopathy: Real-World Survey Data From the United States of America Presenter: Paulos Gebrehiwet, PhD, Senior Manager, Health Economics and Outcomes Research, Europe, Cytokinetics Date: May 10, 2026 Session Title: Comprehensive phenotyping and real-world impact in hypertrophic cardiomyopathy Session Time : 10:30 AM – 11:15 AM CEST Location: Moderated ePosters 3

Title: Impact of Guideline-Directed Medical Therapies on Clinical and Economic Outcomes in Nonobstructive Hypertrophic Cardiomyopathy: Analysis of Data from a Multinational Cross-Sectional Survey Presenter: Paulos Gebrehiwet, PhD, Senior Manager, Health Economics and Outcomes Research, Europe, Cytokinetics, South San Francisco, CA Date: May 10, 2026 Session Title: Comprehensive phenotyping and real-world impact in hypertrophic cardiomyopathy Session Time : 10:30 AM – 11:15 AM CEST Location: Moderated ePosters 3

ePoster Presentations

Title: Impact of Hypertrophic Cardiomyopathy on Work Productivity and Activity Impairment in Patients with HCM: Analysis of a Real-World Cross-Sectional Survey Presenter: Paulos Gebrehiwet, PhD, Senior Manager, Health Economics and Outcomes Research, Europe, Cytokinetics, South San Francisco, CA Date: May 9, 2026 Session Title: ePosters in myocardial disease - hypertrophic cardiomyopathy (2) Session Time: 8:30 AM – 5:30 PM CEST Presentation Time: 8:30 AM – 9:30 AM CEST Location: ePosters screen 22

Title: Phenotypic Distribution and Clinical Burden of Pediatric Hypertrophic Cardiomyopathy: Insights From a Longitudinal US Claims Database Presenter: Jennifer Conway, MD, FRCPC, MSc, Professor of Pediatrics, Director of the Heart Function and Cardiomyopathy Program, Stollery Children’s Hospital, Edmonton, Canada Date: May 10, 2026 Session Title : ePosters in myocardial disease - hypertrophic cardiomyopathy (2) Session Time: 8:30 AM – 5:30 PM CEST Presentation Time: 4:30 PM – 5:30 PM CEST Location: ePosters screen 22

About MYQORZO ® ( aficamten )

MYQORZO ® ( aficamten ) is a cardiac myosin inhibitor approved in the U.S., China and European Union for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM). In patients with oHCM, myosin inhibition with MYQORZO reduces cardiac contractility and consequently, left ventricular outflow tract (LVOT) obstruction. MYQORZO was engineered to achieve a predictable exposure response, rapid onset of action and reversibility. 1

Aficamten is also under clinical investigation in ACACIA-HCM, a Phase 3 trial in patients with non-obstructive HCM (nHCM) and CEDAR-HCM, in a pediatric population with oHCM. Aficamten has not been deemed safe or effective for use in either of these patient populations. In addition, aficamten is being studied in FOREST-HCM, an open-label extension clinical study.

INDICATIONS AND USAGE

MYQORZO is indicated for the treatment of adults with symptomatic oHCM to improve functional capacity and symptoms.

IMPORTANT SAFETY INFORMATION

WARNING: RISK OF HEART FAILURE MYQORZO reduces left ventricular ejection fraction (LVEF) and can cause heart failure due to systolic dysfunction. Echocardiogram assessments are required prior to and during treatment with MYQORZO to monitor for systolic dysfunction. Initiation of MYQORZO in patients with LVEF CONTRAINDICATIONS

MYQORZO is contraindicated with concomitant use of rifampin.

WARNING AND PRECAUTIONS

Heart Failure

MYQORZO reduces cardiac contractility, which can reduce LVEF and cause heart failure. Patients who experience a serious intercurrent illness (eg, serious infection) or arrhythmia (eg, new or uncontrolled atrial fibrillation) may be at greater risk of developing systolic dysfunction and heart failure.

Assess patients’ clinical status and LVEF prior to and during treatment and adjust the MYQORZO dose accordingly. New or worsening arrhythmia, dyspnea, chest pain, fatigue, leg edema, or elevations in N-terminal pro-B-type natriuretic peptide may be signs and symptoms of heart failure.

Initiation of MYQORZO in patients with LVEF 5% of patients and more commonly on MYQORZO than on placebo in the pivotal trial.

Please see full Prescribing Information , including Boxed WARNING and Medication Guide .

About Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy (HCM) is a disease in which the heart muscle becomes abnormally thick. HCM can be obstructive, when thickened muscle blocks blood flow, or non-obstructive, when blood flow is not blocked but heart function is still affected. In obstructive HCM, the thickening of cardiac muscle leads to the inside of the left ventricle becoming smaller, stiffer and less able to relax and fill with blood. Ultimately, HCM limits the heart’s pumping function, leading to reduced exercise capacity and a variety of symptoms.

HCM is the most common monogenic inherited cardiovascular disorder, with well over 300,000 patients diagnosed in the U.S. 2 However, there are an estimated 400,000-800,000 additional patients who remain undiagnosed. 3 , 4 , 5 Approximately half of patients with HCM have obstructive HCM (oHCM) and half have non-obstructive HCM (nHCM). 2

People with HCM are at high risk of also developing cardiovascular complications including atrial fibrillation, stroke and mitral valve disease. 6 People with HCM are at risk for potentially fatal ventricular arrhythmias and it is one of the leading causes of sudden cardiac death in younger people or athletes. 7 A subset of patients with HCM are at high risk of progressive disease leading to dilated cardiomyopathy and heart failure necessitating cardiac transplantation.

About Cytokinetics

Cytokinetics is a specialty cardiovascular biopharmaceutical company, building on its over 25 years of pioneering scientific innovations in muscle biology, and advancing a pipeline of potential new medicines for patients suffering from diseases of cardiac muscle dysfunction. Cytokinetics’ MYQORZO ® ( aficamten ) is a cardiac myosin inhibitor approved in the U.S., Europe and China for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). Aficamten is also being studied for the potential treatment of non-obstructive HCM. Cytokinetics is also developing omecamtiv mecarbil , an investigational cardiac myosin activator for the potential treatment of patients with heart failure with severely reduced ejection fraction and ulacamten , an investigational cardiac myosin inhibitor for the potential treatment of heart failure with preserved ejection fraction, while continuing pre-clinical research and development in muscle biology.

For additional information about Cytokinetics, visit www.cytokinetics.com and follow us on X , LinkedIn , Facebook and YouTube .

Forward-Looking Statements

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the “Act”). Cytokinetics disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act's safe harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements, express or implied, related to Cytokinetics’ research and development activities; clinical trial initiation, design, enrollment, conduct, progress, continuation, completion, timing and results; regulatory submissions, review processes, approval timing and outcomes, including with respect to supplemental applications and approvals in jurisdictions outside the United States; the scope, expansion, modification, durability or continuation of labeling and promotional claims; commercial readiness, launch timing, market access and reimbursement; anticipated patient, prescriber and payer adoption; expectations regarding market opportunity, growth and market share; pipeline development and expansion into additional indications or geographies; access to and use of capital; and Cytokinetics’ business strategy, objectives and future plans. Such statements are based on management's current expectations and assumptions; however, actual results may differ materially due to various risks and uncertainties, including, but not limited to, uncertainties inherent in drug development and commercialization; the timing, conduct and outcomes of clinical trials; regulatory review and approval processes in the United States and other jurisdictions; differences in regulatory requirements, labeling, market access or promotional restrictions across jurisdictions; the ability to obtain, expand, maintain or continue desired labeling, promotional claims or commercial positioning for approved products; potential legal, intellectual property or regulatory constraints affecting commercialization and marketing claims; patient and prescriber acceptance of MYQORZO as compared to alternative therapies; the availability and terms of reimbursement from commercial and government payers; manufacturing, supply and distribution risks; competition; and the availability of sufficient capital to execute Cytokinetics’ business plans. These forward-looking statements speak only as of the date they are made, and Cytokinetics undertakes no obligation to subsequently update any such statement, except as required by law. For further information regarding these and other risks related to Cytokinetics’ business, investors should consult Cytokinetics’ filings with the Securities and Exchange Commission (the “SEC”).

CYTOKINETICS ® and the CYTOKINETICS C-shaped logo are registered trademarks of Cytokinetics in the U.S. and certain other countries.

MYQORZO ® is a registered trademark of Cytokinetics in the U.S. and the European Union.

Contact: Cytokinetics Diane Weiser Senior Vice President, Corporate Affairs (415) 290-7757

References

Hartman JJ, Hwee DT, Roebrt-Paganin J, et al. Aficamten is a small-molecule cardiac myosin inhibitor designed to treat hypertrophic cardiomyopathy. Nat Cardiovasc Res. 2024;3(8) :1003-1016. doi:10.1038/s44161-024-00505-0

Butzner M, et al. Epidemiology of Hypertrophic Cardiomyopathy in the United States From 2016 to 2023. JACC Adv. 2026. 2026;5(2):102552. doi:10.1016/j.jacadv.2025.102552

CVrg: Heart Failure 2020-2029, p 44; Maron et al. 2013 doi:10.1016/S0140-6736(12)60397-3; Maron et al 2018 10.1056/NEJMra1710575

Symphony Health 2016-2021 Patient Claims Data DoF;

Maron MS, Hellawell JL, Lucove JC, Farzaneh-Far R, Olivotto I. Occurrence of Clinically Diagnosed Hypertrophic Cardiomyopathy in the United States. Am J Cardiol. 2016; 15;117(10):1651-1654.

Gersh, B.J., Maron, B.J., Bonow, R.O., Dearani, J.A., Fifer, M.A., Link, M.S., et al. 2011 ACCF/AHA guidelines for the diagnosis and treatment of hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Journal of the American College of Cardiology and Circulation, 58, e212-260.

Hong Y, Su WW, Li X. Risk factors of sudden cardiac death in hypertrophic cardiomyopathy. Current Opinion in Cardiology. 2022 Jan 1;37(1):15-21
## Recent Company News
- 2026-07-23 20:00 EST — [Cytokinetics to Announce Second Quarter Results on August 6, 2026](https://biopharmsignal.com/news/CYTK/cytokinetics-to-announce-second-quarter-results-on-august-6-2026-18350192) — Source: Cytokinetics
- 2026-07-17 20:00 EST — [Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/CYTK/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-1e80a7fe) — Source: Cytokinetics
- 2026-07-07 11:30 EST — [Cytokinetics Announces Three Late-Breaking Science Abstracts at the European Society of Cardiology (ESC) Congress 2026](https://biopharmsignal.com/news/CYTK/cytokinetics-announces-three-late-breaking-science-abstracts-at-the-european-soc-852ccfe1) — Source: Cytokinetics
- 2026-06-17 20:00 EST — [Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/CYTK/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-12014bdd) — Source: Cytokinetics
- 2026-06-08 11:30 EST — [Cytokinetics Announces Call for Proposals for Annual Corporate Giving Program](https://biopharmsignal.com/news/CYTK/cytokinetics-announces-call-for-proposals-for-annual-corporate-giving-program-d243df03) — Source: Cytokinetics
## Related News
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)
- 2026-07-29 12:25 EST — ICCM — [IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance  of ProSense®](https://biopharmsignal.com/news/ICCM/icecure-sio-petitions-nccn-to-include-cryoablation-in-breast-cancer-treatment-gu-bec46cd3)